Introduction: The Foundation of Injectable Container Closure Integrity
In the pharmaceutical industry, the elastomeric closure—commonly referred to as a rubber stopper, plunger, or seal—performs what can only be described as a remarkable feat of materials engineering. A stainless steel needle pierces the closure clear through to the other side, breaching the barrier that protects an inner sterile environment from the outer world. The closure material yields just enough for the needle to easily penetrate, while simultaneously closing tightly around the needle without fragmenting, splintering, or crumbling. After the syringe withdraws drug content from the vial, the needle is removed and the closure material reseals, again forming an impervious barrier. For many weeks prior, this closure has already formed a tight seal in the vial, preventing entry of outer microbes and chemicals through shipping, storage, and temperature and pressure fluctuations, all without leaching lubricants, colorants, or other additives into the drug product.
The “simple” vial stopper is truly a great example of high-end pharmaceutical technology. But what tests are performed to ensure this miracle product performs as advertised? The minimum testing expectations for such closures are outlined in USP <381> Elastomeric Closures for Injections.
At Vialab Pharmaceutical Packaging Co., Ltd. , we understand that the stopper is the critical interface between the drug product and the outer environment. While our core expertise lies in aluminum caps and aluminum-plastic combination caps, we recognize that the complete container closure system—vial, stopper, and cap—must function as an integrated whole. Our caps are designed and manufactured to work seamlessly with USP <381>-compliant elastomeric closures, ensuring consistent quality, integrity, and compliance for global healthcare partners.
This article provides a comprehensive examination of USP <381>—exploring its scope, key requirements, test categories, classification system, and the significant regulatory changes taking effect in 2025.
1. Scope and Applicability of USP <381>
1.1 Definition and Purpose
USP <381> applies to elastomeric closures for containers used in the types of preparations defined in General Chapter Injections (1). An elastomeric closure is defined as a packaging component that is, or may be, in direct contact with the drug.
Elastomeric closures are made of materials obtained by vulcanization (cross-linking) polymerization, polyaddition, or polycondensation of macromolecular organic substances (elastomers). Closure formulations contain natural or synthetic elastomers and inorganic and organic additives to aid or control vulcanization, impart physical and chemical properties or color, or stabilize the closure formulation.
The purpose of this chapter is to provide baseline chemical and biological reactivity requirements for the selection of elastomeric injectable packaging/delivery system components. It is intended as an initial screen to identify elastomeric closures that, on the basis of their biological compatibility, their aqueous extract physicochemical properties, and their functionality, may be appropriate for use with injectable preparations.
1.2 Materials Covered
The chapter applies to closures formulated with natural or synthetic elastomeric substances. It does not apply to closures made from silicone elastomer, but it does apply to closures treated with silicone (e.g., dimethicone, NF).
For laminated or coated closures (e.g., polytetrafluoroethylene (PTFE) or lacquer coatings), the physicochemical tests apply to the base elastomer, while the functionality tests apply to and should be performed using the entire laminated or coated elastomeric closure.
1.3 Beyond the Scope of USP <381>
USP <381> explicitly states that the following closure evaluation requirements are beyond its scope:
- The establishment of closure identification tests and specifications
- The verification of closure-product physicochemical compatibility
- The identification and safety determination of closure leachables found in the packaged product
- The verification of packaged product closure functionality under actual storage and use conditions
As noted in the Introduction to USP <381>, these tests are intended only as an initial safety evaluation. Verification of the safety of closure leachables in the packaged product must still be performed as part of a full package development process.
2. The Three Pillars of USP <381> Testing
USP <381> organizes its requirements into three distinct categories: Biological Tests, Physicochemical Tests, and Functionality Tests.
2.1 Biological Tests
The biological tests are designed to evaluate the safety of the elastomeric closure material. Two stages of testing are indicated:
Stage 1 – In Vitro Testing: Performed according to the procedures set forth in USP <87> Biological Reactivity Tests, In Vitro.
Stage 2 – In Vivo Testing: Materials that do not meet the requirements of the in vitro tests are subjected to in vivo testing, i.e., the Systemic Injection Test and Intracutaneous Test, according to USP <88> Biological Reactivity Tests, In Vivo.
The biological tests are intended only as an initial safety evaluation. If elastomeric components comply with the biological reactivity and physicochemical requirements, they may be considered suitable for further evaluation as part of a complete container closure system.
2.2 Physicochemical Tests
The physicochemical tests are designed to determine pertinent extraction characteristics of elastomeric closures. Since the tests are based on the extraction of the elastomer, it is essential that the designated amount of surface area of sample be available.
Sample Preparation: A sufficient number of elastomeric closures are placed in a suitable extraction container to provide 100 cm² of exposed surface area.
Extraction Solvents:
- A: Purified Water
- B: Drug product vehicle (where applicable)
- C: Isopropyl alcohol
Apparatus Requirements:
- Autoclave: Capable of maintaining 121 ± 2°C, equipped with thermometer, pressure gauge, and rack
- Oven: Forced-draft model maintaining 105 ± 2°C
- Reflux Apparatus: Capacity of about 500 mL
Key Physicochemical Tests:
| Test | Description |
|---|---|
| Turbidity | Nonspecific test for extractable species not soluble in aqueous solution |
| Reducing Agents | Permanganate-reducing substances in purified water extract |
| Heavy Metals | USP <231> test for extractable heavy metals |
| Extractable Zinc | Quantitative assessment of zinc in extract |
| pH Impact | pH of extract versus blank |
| Total Extractables | Gravimetric analysis of dried extract |
| Absorbance | UV absorbance of extract at 220–360 nm |
| Ammonium | Colorimetric test |
| Volatile Sulfides | Colorimetric test |
| Colorants | Visual comparison |
The physicochemical tests are orthogonal in that they provide a general overview of extracted chemical entities, while the Extractable Elements Test provides a quantitative assessment of extractable elements of concern.
2.3 Functionality Tests
The functionality tests evaluate the fitness of an elastomeric closure intended to be pierced by a hypodermic needle. Three specific tests are defined:
Penetrability: Measures the force required for a needle to pierce the closure. The force for piercing must be no greater than 10 N (1 kgf) for each closure. The test uses a lubricated long bevel hypodermic needle (bevel angle 12 ± 2°) per ISO 7864.
Fragmentation: Evaluates whether the closure fragments, splinters, or crumbles when pierced. Fragments are detected through visual observation of the filtrate.
Self-Sealing Capacity: Assesses whether the closure reseals after needle withdrawal, maintaining an impervious barrier. Tested through visual observation after vacuum soak in methylene blue.
These functionality tests apply to closures both as shipped by the closure supplier to the injectable product manufacturer and in their final ready-to-use state.
3. Type I and Type II Classification
USP <381> establishes test limits for two classifications of elastomeric closures:
Type I Closures: Used for aqueous preparations. Type I closures must meet more stringent requirements, particularly for UV absorbance and reducing substances.
Type II Closures: Typically intended for nonaqueous preparations. Type II closures are those that, because they have properties optimized for special uses, may not meet all requirements listed for Type I closures due to physical configuration, material of construction, or both.
If a closure fails to meet one or more of the Type I test requirements but still meets the Type II requirements for the test(s), the closure is assigned a final classification of Type II.
All elastomeric closures suitable for use with injectable preparations must comply with either Type I or Type II test limits. However, this specification is not intended to serve as the sole evaluation criterion for the selection of such closures.
The revised chapter includes classification criteria for Type I and II closures, as well as the addition of identification tests.
4. The 2009 Revision: A Significant Enhancement
Prior to May 1, 2009, USP <381> required only a handful of biological and physicochemical tests. The 2009 revision greatly increased the testing requirements to better reflect the important role that this component plays.
Key changes introduced in the 2009 revision included:
- Enhanced Physicochemical Tests: Addition of absorbance, ammonium, volatile sulfides, colorants, and identification tests
- New Functional Tests: Penetrability, fragmentation, and self-sealing capacity became mandatory
- Biological Testing Clarification: Two-stage approach (in vitro then in vivo) was formalized
If the pharmaceutical manufacturer has not confirmed performance to these minimal biological, physicochemical, and functional test requirements in the enhanced guideline, it is not in compliance with current guidelines and has not confirmed that the closure is in fact safe to use.
The 2009 revision also established the important principle that elastomeric closures shall conform to biological, physicochemical, and functionality requirements both as they are shipped by the closure supplier and in their final ready-to-use state by the end user.
5. The Relationship Between USP <381> and USP <382>
A significant regulatory change is underway that will reshape how elastomeric closures are evaluated. USP <382> Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems was officially incorporated into USP–NF on December 1, 2020, with a 5‑year implementation delay to allow industry ample time for adoption. It will become official on December 1, 2025.
5.1 The Fundamental Difference
USP <381> refers to the evaluation of elastomeric compounds individually, not considering them as part of a full system. The stopper is evaluated without taking the potential impact of its interactions with the vial, the crimping cap, and the drug product on its functional performances.
USP <382> evaluates the functionality of the complete system instead of the individual elastomeric compounds alone. It includes not only stoppers but also plungers and needle-shields, so systems for injectable applications—vials, PFSs, and cartridges—are included.
5.2 What Changes on December 1, 2025
Following the USP compendial notice published on April 25, 2025:
- USP <381> will remain the reference for biological reactivity and physicochemical tests
- Functionality Tests (section 4.3) will be removed from USP <381> as they will be redundant due to USP <382>
- Fragmentation testing will remain applicable as described in USP <381>
- Penetrability and self-sealing tests will be omitted from USP <381> and included in USP <382>
Pharmaceutical companies, being the stakeholders owning the complete packaging information, will be responsible for checking the full compliance of their systems toward USP <382>. The main recommendation from USP <382> is to evaluate the full system according to its final intended use.
5.3 What Remains in USP <381>
After December 1, 2025, USP <381> will continue to focus on:
- Biological reactivity testing (USP <87> and <88>)
- Physicochemical testing (turbidity, reducing agents, heavy metals, extractable zinc, pH, total extractables, absorbance, ammonium, volatile sulfides, colorants)
- Material characterization of the elastomeric compound
- Type I and Type II classification
The physicochemical tests for elastomer characterization described in USP <381> will remain in effect.
6. Practical Considerations for Pharmaceutical Manufacturers
6.1 Supplier Qualification and Documentation
The manufacturer of the injectable product must obtain from the closure supplier an assurance that the composition of the closure does not vary and that it is the same as that of the closure used during compatibility testing. When the supplier informs the end user of changes in the composition, the latter must repeat compatibility testing, totally or partly, depending on the nature of the changes.
For all USP <381> tests performed on any closure type, it is important to document the closure being tested, including a full description of the elastomer, and any lubrication, coating, laminations, or treatments applied.
6.2 Global Harmonization
USP <381> has been harmonized with the European Pharmacopoeia (Ph. Eur. 3.2.9). The combined protocol satisfies both the Ph. Eur. and USP requirements for elastomeric closures for injection, and the texts of the Ph. Eur. and USP chapters are nearly identical.
This harmonization extends to other global standards including ISO 8871 series and Japanese Pharmacopoeia JP 7.03. Both ISO 8871‑5 and USP <381> provide comprehensive guidelines for testing the functional requirements of elastomeric parts used in pharmaceutical applications. Although test details may vary slightly, both standards share the objective of ensuring closure integrity while maintaining usability.
6.3 Preparing for the USP <382> Transition
Pharmaceutical companies should take the following steps to prepare for the December 1, 2025 effective date:
- Review current USP <381> functionality testing protocols and assess how they will need to be adapted for system-level testing under USP <382>
- Develop system-level testing methods that represent real-life conditions of use
- Establish acceptance criteria for the complete container closure system
- Ensure supply chain visibility to verify that elastomeric components meet both USP <381> (biological and physicochemical) and USP <382> (functional) requirements
While USP <382> does not impose specific specifications, it provides pharmaceutical companies with guidelines to develop testing methods that best represent their systems’ real-life conditions of use.
7. Vialab’s Commitment to Container Closure System Excellence
At Vialab Pharmaceutical Packaging Co., Ltd. , we recognize that the elastomeric closure is the critical sealing interface in any injectable container closure system. While our core products are aluminum caps and aluminum-plastic combination caps, we understand that these components must work in perfect harmony with USP <381>-compliant stoppers to ensure container closure integrity.
Our commitment to quality encompasses:
- Dimensional precision: Our caps are manufactured to tolerances that ensure proper crimping force distribution, maintaining stopper compression without over-compression that could compromise the elastomeric seal
- Compatibility validation: We work with our partners to ensure that our caps are compatible with their chosen stopper systems
- Comprehensive documentation: We provide full traceability of our products, supporting our partners’ USP <381> and <382> compliance efforts
- Regulatory expertise: We stay current with evolving USP standards, including the transition to USP <382>
Whether you require 13 mm, 20 mm, or 32 mm aluminum caps or aluminum-plastic combination caps, Vialab delivers components designed to work seamlessly with USP <381>-compliant elastomeric closures.
Conclusion
USP <381> Elastomeric Closures for Injections establishes the foundational requirements for the safety, quality, and performance of elastomeric closures used in injectable pharmaceutical packaging. Through its three pillars of testing—biological, physicochemical, and functional—the standard ensures that closures meet minimum requirements for biocompatibility, extractable profile, and needle-penetration performance.
The classification of closures into Type I (for aqueous preparations) and Type II (for nonaqueous preparations) provides a framework for selecting appropriate closures based on the drug product’s formulation and requirements.
The upcoming implementation of USP <382> on December 1, 2025 represents a significant evolution in the regulatory landscape. Functionality testing will shift from component-level evaluation to system-level evaluation, placing greater responsibility on pharmaceutical manufacturers to demonstrate that the complete container closure system—vial, stopper, and cap—performs as intended under real-world conditions.
As the pharmaceutical industry continues to advance, the importance of robust container closure systems will only grow. At Vialab, we remain committed to supporting our partners with high-quality packaging components and the technical expertise needed to navigate the evolving regulatory landscape.
References
- USP <381> – Elastomeric Closures for Injections
- USP <382> – Elastomeric Component Functional Suitability in Parenteral Product Packaging/Delivery Systems
- USP <87> – Biological Reactivity Tests, In Vitro
- USP <88> – Biological Reactivity Tests, In Vivo
- USP <1207> – Package Integrity Evaluation — Sterile Products
- Ph. Eur. 3.2.9 – Rubber Closures for Containers for Aqueous Parenteral Preparations, for Powders and for Freeze-Dried Powders
- ISO 8871-5 – Elastomeric parts for parenterals and for devices for pharmaceutical use — Part 5: Functional requirements and testing
- ISO 7864 – Sterile hypodermic needles for single use — Requirements and test methods
- 21 CFR Part 211 – Current Good Manufacturing Practice for Finished Pharmaceuticals
- FDA Guidance for Industry: Container Closure Systems for Packaging Human Drugs and Biologics
This article is provided for informational purposes only and does not constitute regulatory advice. Manufacturers should consult with qualified experts and regulatory authorities for specific product validation and compliance.